ReShape Total Current Assets vs Retained Earnings Analysis
| RSLS Stock | USD 0.25 0.03 10.71% |
ReShape Lifesciences financial indicator trend analysis is much more than just breaking down ReShape Lifesciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ReShape Lifesciences is a good investment. Please check the relationship between ReShape Lifesciences Total Current Assets and its Retained Earnings accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.
Total Current Assets vs Retained Earnings
Total Current Assets vs Retained Earnings Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ReShape Lifesciences Total Current Assets account and Retained Earnings. At this time, the significance of the direction appears to have almost no relationship.
The correlation between ReShape Lifesciences' Total Current Assets and Retained Earnings is 0.19. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of ReShape Lifesciences, assuming nothing else is changed. The correlation between historical values of ReShape Lifesciences' Total Current Assets and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of ReShape Lifesciences are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Total Current Assets i.e., ReShape Lifesciences' Total Current Assets and Retained Earnings go up and down completely randomly.
Correlation Coefficient | 0.19 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most indicators from ReShape Lifesciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ReShape Lifesciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.At this time, ReShape Lifesciences' Selling General Administrative is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.20 in 2024, whereas Tax Provision is likely to drop (36.8 K) in 2024.
ReShape Lifesciences fundamental ratios Correlations
Click cells to compare fundamentals
ReShape Lifesciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ReShape Lifesciences fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 39.7M | 37.1M | 54.3M | 11.1M | 10.7M | 10.2M | |
| Total Stockholder Equity | 24.1M | 14.5M | 46.1M | 3.7M | 6.7M | 6.3M | |
| Retained Earnings | (493.2M) | (514.8M) | (576.8M) | (624.2M) | (635.6M) | (603.8M) | |
| Other Assets | 99K | 46K | 1.5M | 102K | 117.3K | 111.4K | |
| Common Stock Shares Outstanding | 31.4K | 26.0K | 218.5K | 424.4K | 6.0M | 6.3M | |
| Liabilities And Stockholders Equity | 39.7M | 37.1M | 54.3M | 11.1M | 10.7M | 10.2M | |
| Other Stockholder Equity | 517.3M | 529.4M | 622.9M | 627.9M | 642.3M | 323.4M | |
| Total Liab | 15.6M | 22.6M | 8.2M | 7.5M | 4.1M | 3.9M | |
| Short Long Term Debt Total | 768K | 477K | 279K | 171K | 262K | 248.9K | |
| Other Current Liab | 5.6M | 7.2M | 3.0M | 4.9M | 1.3M | 1.3M | |
| Total Current Liabilities | 10.4M | 11.6M | 7.3M | 7.5M | 3.8M | 6.0M | |
| Property Plant And Equipment Net | 774K | 1.0M | 1.7M | 869K | 310K | 600.4K | |
| Net Debt | (2.2M) | (2.5M) | (22.5M) | (3.7M) | (4.3M) | (4.5M) | |
| Accounts Payable | 4.3M | 3.7M | 3.5M | 1.9M | 1.7M | 1.3M | |
| Cash | 2.9M | 3.0M | 22.8M | 3.9M | 4.6M | 4.3M | |
| Non Current Assets Total | 29.5M | 28.1M | 24.0M | 1.2M | 431K | 409.5K | |
| Non Currrent Assets Other | 562.9K | 99K | 46K | 1.5M | 29K | 27.6K | |
| Cash And Short Term Investments | 2.9M | 3.0M | 22.8M | 3.9M | 4.6M | 4.3M | |
| Net Receivables | 4.1M | 2.6M | 2.8M | 2.2M | 1.7M | 997.2K | |
| Non Current Liabilities Total | 5.2M | 11.0M | 855K | 2.6M | 287.0K | 272.6K | |
| Other Current Assets | 1.7M | 1.1M | 1.6M | 84K | 337K | 320.2K | |
| Property Plant And Equipment Gross | 774K | 1.0M | 1.7M | 1.2M | 400K | 618.1K | |
| Total Current Assets | 10.1M | 8.9M | 30.3M | 9.9M | 10.3M | 16.2M | |
| Accumulated Other Comprehensive Income | (8K) | (121K) | (92K) | (88K) | (79.2K) | (83.2K) | |
| Short Term Debt | 291K | 314K | 279K | 171K | 111K | 105.5K | |
| Common Stock | 8K | 6K | 18K | 1K | 23K | 21.9K | |
| Property Plant Equipment | 16K | 584K | 1.7M | 869K | 782.1K | 565.6K | |
| Other Liab | 6.2M | 4.7M | 1.6M | 855K | 983.3K | 934.1K | |
| Current Deferred Revenue | 352K | 202K | 398K | 549K | 639K | 671.0K | |
| Inventory | 1.3M | 2.2M | 3.0M | 3.6M | 3.7M | 3.9M | |
| Net Tangible Assets | (4.6M) | (12.5M) | 25.2M | 3.4M | 3.1M | 4.0M | |
| Retained Earnings Total Equity | (334.8M) | (419.0M) | (493.2M) | (514.8M) | (463.3M) | (486.5M) | |
| Capital Surpluse | 410.8M | 450.6M | 517.3M | 529.4M | 608.8M | 386.1M | |
| Deferred Long Term Liab | 5.3M | 1.8M | 702K | 615K | 707.3K | 929.9K | |
| Intangible Assets | 28.7M | 27.0M | 20.8M | 260K | 299K | 284.1K |
Pair Trading with ReShape Lifesciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ReShape Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ReShape Lifesciences will appreciate offsetting losses from the drop in the long position's value.Moving against ReShape Stock
| 0.53 | WST | West Pharmaceutical | PairCorr |
| 0.44 | SSY | SunLink Health Systems | PairCorr |
| 0.43 | FNA | Paragon 28 | PairCorr |
| 0.41 | CAH | Cardinal Health Fiscal Year End 20th of August 2024 | PairCorr |
The ability to find closely correlated positions to ReShape Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ReShape Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ReShape Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ReShape Lifesciences to buy it.
The correlation of ReShape Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ReShape Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ReShape Lifesciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ReShape Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for ReShape Stock analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is ReShape Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ReShape Lifesciences. If investors know ReShape will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ReShape Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Revenue Per Share 0.732 | Quarterly Revenue Growth (0.15) | Return On Assets (0.57) | Return On Equity (1.78) |
The market value of ReShape Lifesciences is measured differently than its book value, which is the value of ReShape that is recorded on the company's balance sheet. Investors also form their own opinion of ReShape Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is ReShape Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ReShape Lifesciences' market value can be influenced by many factors that don't directly affect ReShape Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ReShape Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ReShape Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ReShape Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.